New clinical trial data for canagliflozin confirmed previously noted risk about fractures and reduced bone mineral density in the hip and spine, prompting the FDA to revise the product label.
News Alerts …read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
